drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
JCPyV-specific virus-specific T-cell therapy (adoptive cellular immunotherapy) consisting of HLA-restricted T cells infused IV (1×10^8 cells every 28 days for 4 doses) to restore antiviral cytotoxic T-lymphocyte responses (primarily CD8+) against JCPyV-infected CNS cells, control viral replication, and slow/stop PML progression.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptive transfer of ex vivo expanded, HLA-restricted JCPyV-specific T cells (primarily CD8+ cytotoxic T lymphocytes) that recognize JCPyV antigens via native TCRs on infected CNS cells and eliminate them via cytotoxic effector functions and Th1 cytokines, restoring antiviral cellular immunity to control viral replication and slow or halt PML progression.
drug_name
CE-VST01-JC
nct_id_drug_ref
NCT05541549